SCHEMBL25728946

SCHEMBL25728946

CC(C)(C)c1nc(C(C)(F)F)c2n1CCNC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23264169 0.91 USP1 (0.33) —
SCHEMBL25718292 0.79 — —
SCHEMBL21998817 0.72 SOD3 (0.32) —
SCHEMBL25517543 0.71 HTR2C (0.33) —
SCHEMBL19705565 0.71 HTR2C (0.33) —
SCHEMBL10025680 0.69 ADRB1 (0.33) —
SCHEMBL27800792 0.68 — —
SCHEMBL23264140 0.68 USP1 (0.30) —
SCHEMBL14962429 0.68 — —
SCHEMBL25463483 0.68 ALDH1A1 (0.32) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787813-B2 Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors KSQ Therapeutics, Inc. (US) 2023-10-17 — — US disclosed
US-20230203046-A1 SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-06-29 — — US disclosed
Send feedback